Mouse Anti-NAXD Recombinant Antibody (CBLC109-LY) (CBMAB-C9715-LY)

Name: Mouse Anti-NAXD Recombinant Antibody (CBLC109-LY)
SKU: CBMAB-C9715-LY
Rating: 5 (1 reviews)

See all NAXD antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBLC109-LY

Application

WB, IP, IF, ELISA

Specificity

Mouse

Antibody Isotype

IgG

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

NAD(P)HX dehydratase

Entrez Gene ID

69225

UniProt ID

Q9CZ42

Alternative Names

0710008K08Rik, 2810407E01Rik, Carkd

Function

Catalyzes the dehydration of the S-form of NAD(P)HX at the expense of ATP, which is converted to ADP. Together with NAD(P)HX epimerase, which catalyzes the epimerization of the S- and R-forms, the enzyme allows the repair of both epimers of NAD(P)HX, a damaged form of NAD(P)H that is a result of enzymatic or heat-dependent hydration.

Biological Process

Metabolite repair Source: GO_Central
NAD biosynthesis via nicotinamide riboside salvage pathway Source: Reactome

Cellular Location

Mitochondrion

Involvement in disease

Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2 (PEBEL2):
An autosomal recessive severe neurometabolic disorder characterized by severe leukoencephalopathy usually associated with a trivial febrile illness. Affected infants tend to show normal early development followed by acute psychomotor regression with ataxia, hypotonia, respiratory insufficiency, and seizures. Disease course is rapidly progressive, leading to coma, global brain atrophy, and death in the first years of life. Brain imaging shows multiple abnormalities, including brain edema and signal abnormalities in the cortical and subcortical regions.

Van Bergen, N. J., Gunanayagam, K., Bournazos, A. M., Walvekar, A. S., Warmoes, M. O., Semcesen, L. N., ... & Christodoulou, J. (2023). Severe NAD (P) HX Dehydratase (NAXD) Neurometabolic Syndrome May Present in Adulthood after Mild Head Trauma. International Journal of Molecular Sciences, 24(4), 3582.

Van Bergen, N. J., Walvekar, A. S., Patraskaki, M., Sikora, T., Linster, C. L., & Christodoulou, J. (2022). Clinical and biochemical distinctions for a metabolite repair disorder caused by NAXD or NAXE deficiency. Journal of Inherited Metabolic Disease, 45(6), 1028-1038.

Oz Tuncer, G., Randa, N. C., Aydin, S., & Aksoy, A. (2022). A Case with NAD (P) HX Dehydratase (NAXD) Deficiency: A Newly Defined Mutation in a Novel Neurodegenerative Disorder. Molecular Syndromology, 13(4), 332-336.

Manor, J., Calame, D., Gijavanekar, C., Fisher, K., Hunter, J., Mizerik, E., ... & Elsea, S. H. (2022). NAXE deficiency: A neurometabolic disorder of NAD (P) HX repair amenable for metabolic correction. Molecular genetics and metabolism, 136(2), 101-110.

Majethia, P., Mishra, S., Rao, L. P., Rao, R., & Shukla, A. (2021). NAD (P) HX dehydratase (NAXD) deficiency due to a novel biallelic missense variant and review of literature. European Journal of Medical Genetics, 64(9), 104266.

Borna, N. N., Kishita, Y., Abe, J., Furukawa, T., Ogawa-Tominaga, M., Fushimi, T., ... & Okazaki, Y. (2020). NAD (P) HX dehydratase protein-truncating mutations are associated with neurodevelopmental disorder exacerbated by acute illness. Brain, 143(7), e54-e54.

Zhou, J., Li, J., Stenton, S. L., Ren, X., Gong, S., Fang, F., & Prokisch, H. (2020). NAD (P) HX dehydratase (NAXD) deficiency: a novel neurodegenerative disorder exacerbated by febrile illnesses. Brain, 143(2), e8-e8.

Van Bergen, N. J., Linster, C. L., & Christodoulou, J. (2020). Reply: NAD (P) HX dehydratase protein-truncating mutations are associated with neurodevelopmental disorder exacerbated by acute illness. Brain, 143(7), e55-e55.

Malik, M. U., Nadir, H., Jessop, Z. M., & Cubitt, J. J. (2020). Cutaneous manifestations of NAXD deficiency–A case report. Annals of Medicine and Surgery, 60, 352-355.

Van Bergen, N. J., Guo, Y., Rankin, J., Paczia, N., Becker-Kettern, J., Kremer, L. S., ... & Hakonarson, H. (2019). NAD (P) HX dehydratase (NAXD) deficiency: a novel neurodegenerative disorder exacerbated by febrile illnesses. Brain, 142(1), 50-58.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-NAXD Recombinant Antibody (CBLC109-LY)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry